Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG)
CAPS Rating:
The Company is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs.
The Company is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs.
Recs
I know it's a biotech and some of the rules thus change, but that jump makes it look like the ripe time to get out of Dodge. I can't see this sustaining or even matching the market.